Molecular Biotechnology Programme
Uppsala University School of Engineering
UPTEC X 07 047 Date of issue 2007-09
Author
Anna Engström
Title (English)
Screening for anti-virulence compounds against Escherichia coli and investigation of triclosan resistance development in
Staphylococcus aureus
Title (Swedish) Abstract
Two strategies to find treatments against nosocomial infections were investigated in this degree project. Anti-virulence is a new concept for antibacterial therapy. Anti-virulence drugs render pathogenic bacteria sensitive to the complement system so that they can be cleared from the body in a natural way. In the first part of the project a high-throughput screening of 14 727 synthetic compounds was performed on Escherichia coli. The other part was involved in the development of a novel antibiotic drug, a FabI inhibitor. The aim was to generate a triclosan resistant Staphylococcus aureus strain for cross-resistance studies with triclosan and to investigate the underlying resistance mechanism of the obtained clones as well as of an S.
aureus strain resistant to the FabI inhibitor MUT021142-00-B.
Keywords
Nosocomial infections, anti-virulence, complement system, high-throughput screening, Escherichia coli, antibiotics, FabI, Staphylococcus aureus, triclosan
Supervisors
Coralie Soulama-Mouzé
Mutabilis SA, Romainville, France Scientific reviewer
Diarmaid Hughes
Department of Cell and Molecular Biology, Uppsala University
Project name Sponsors
Language
English
Security
Secret until 2012-01-29
ISSN 1401-2138 Classification
Supplementary bibliographical information Pages
46
Biology Education Centre Biomedical Center Husargatan 3 Uppsala Box 592 S-75124 Uppsala Tel +46 (0)18 4710000 Fax +46 (0)18 555217